 |
Prospector
Profile
3-20-001
|
| |
| Acura Pharmaceuticals, Inc. |
NAICS |
325412 |
| 616 N North Ct,
Palatine, IL 60067 |
Description |
Pharmaceutical Preparation Mfg. |
| (847) 705-7709 |
Employees |
14 |
| http://www.acurapharm.com/ |
Revenue |
(mil) |
6.4000 |
| |
Income |
(mil) |
-4.3100 |
| |
Assets |
(mil) |
45.6300 |
| |
Liability |
(mil) |
26.9100 |
| |
(for the year ended 2007-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Acura Pharmaceuticals, Inc., had a net loss of $4.31 million for the year ended December 31, 2007, which is lower than the net losses of $5.97 million and $12.08 during the years ended 2006 and 2005, respectively. The Company reported total revenue of $6.40 million for the year ended December 31, 2007, as compared to none during the previous fiscal years. As a result of its recurring losses, the Company's balance sheet at December 31, 2007, showed an accumulated deficit of $321.86 million.
|
| |
|
Intellectual Property:
In April 2007, the United States Patent and Trademark Office issued to the Company U.S. Patent No. 7,201,920 titled Methods and Compositions for Deterring Abuse of Opioid Containing Dosage Forms. The 54 allowed patent claims encompass pharmaceutical compositions intended to reduce or discourage the most common methods of prescription opioid analgesic product misuse and abuse. The opioid analgesics in the issued patent claims include oxycodone, hydrocodone, hydromorphone, morphine, codeine, tramadol, propoxyphene and many others. In addition to issued U.S. Patent No. 7,201,920, as of February 1, 2008, the Company has pending five U.S. non-provisional pending patent applications, three WO/PCT pending patent applications and multiple additional U.S. provisional and international patent filings relating to compositions containing abuseable drugs. The Company has retained all of the intellectual property rights to its Aversion(R) Technology and related product candidates. [SEC Filing 10-K 03-05-08]
|
| |
|
Description:
Acura Pharmaceuticals, Inc., focuses on research, development, and manufacture of abuse deterrent, abuse resistant, and tamper resistant formulations intended for use in orally administered pharmaceutical products.
|
| |
|
Officers:
Andrew D. Reddick (Pres., CEO & Dir.); Ron J. Spivey (SVP & Chief Scientific Officer); Peter A. Clemens (SVP, CFO & Sec.); James F. Emigh (VP-Mktg. & Admin.);
Robert A. Seiser (VP-Corp. Controller & Treas.); Bruce F. Wesson (Dir.); William A. Sumner (Dir.); Richard J. Markham (Dir.); William G. Skelly (Dir.); Immanuel Thangaraj (Dir.); George K. Ross (Dir.)
|
| |
|
Auditor:
BDO Seidman LLP
|
| |
|
Securities:
Common Stock Symbol ACUR; NasdaqCM; 42,706,466 common shares outstanding as of March 1, 2008.
|
| |
| |
| |
| return to main page |
|
|
